A gene-therapy medicine has been given commercial approval in Europe for the first time. <\/p>\n
The treatment, Glybera, is designed to help those suffering from lipoprotein lipase deficiency -- an inherited disorder which sees patients unable to break down fats and can lead to life-threatening pancreatitis attacks. <\/p>\n
Glybera -- the brand name for alipogene tiparvovec -- works on the genetic level by using a virus to implant working copies of the lipoprotein lipase gene into muscle cells, thus enabling production of the enzyme in those cells. <\/p>\n
The first country to approve a gene therapy for commercial use was China in 2003 but gene therapy in Europe has, until now, been restricted to research laboratories. <\/p>\n
Jorn Aldag, CEO of Glybera creators UniQure, said: \"The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need.\" <\/p>\n
The treatment is expected to come to market in 2013. <\/p>\n
Image: Shutterstock <\/p>\n<\/p>\n
See the original post:<\/p>\n
First commercial gene therapy approved for Europe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" A gene-therapy medicine has been given commercial approval in Europe for the first time. The treatment, Glybera, is designed to help those suffering from lipoprotein lipase deficiency -- an inherited disorder which sees patients unable to break down fats and can lead to life-threatening pancreatitis attacks. Glybera -- the brand name for alipogene tiparvovec -- works on the genetic level by using a virus to implant working copies of the lipoprotein lipase gene into muscle cells, thus enabling production of the enzyme in those cells. Continue reading